Abstract
There is growing evidence of the importance of mucosal healing (MH) in ulcerative colitis, but whether or not it should be a future primary treatment goal is still under intense discussion. Within the last decade many clinical trials have focused not only on response and remission rates but also on achievement of MH, while in clinical practice we still make treatment decisions on the basis of clinical symptoms. There is so far no internationally accepted definition of MH and the tools for assessment of MH vary from biomarkers to endoscopy with histological evaluation on the basis of several different scores and indices. This review will focus on present data dealing with methods to assess MH and the importance of MH for the future course of disease, the need for colectomy or risk of developing colorectal cancer and the patient’s quality of life. Many questions remain: How and when do we best assess MH? How rapidly do we need to achieve MH? What is the optimal time point to discontinue treatment after achieving MH? Well defined prospective studies are needed to address these important questions.
Keywords: Biomarkers, cancer risk, clinical outcome, hospitalization, imaging, inflammatory bowel disease, mucosal healing, quality of life, relapse, ulcerative colitis.
Current Drug Targets
Title:Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes
Volume: 13 Issue: 10
Author(s): Anja Schirbel and Andreas Sturm
Affiliation:
Keywords: Biomarkers, cancer risk, clinical outcome, hospitalization, imaging, inflammatory bowel disease, mucosal healing, quality of life, relapse, ulcerative colitis.
Abstract: There is growing evidence of the importance of mucosal healing (MH) in ulcerative colitis, but whether or not it should be a future primary treatment goal is still under intense discussion. Within the last decade many clinical trials have focused not only on response and remission rates but also on achievement of MH, while in clinical practice we still make treatment decisions on the basis of clinical symptoms. There is so far no internationally accepted definition of MH and the tools for assessment of MH vary from biomarkers to endoscopy with histological evaluation on the basis of several different scores and indices. This review will focus on present data dealing with methods to assess MH and the importance of MH for the future course of disease, the need for colectomy or risk of developing colorectal cancer and the patient’s quality of life. Many questions remain: How and when do we best assess MH? How rapidly do we need to achieve MH? What is the optimal time point to discontinue treatment after achieving MH? Well defined prospective studies are needed to address these important questions.
Export Options
About this article
Cite this article as:
Schirbel Anja and Sturm Andreas, Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes, Current Drug Targets 2012; 13 (10) . https://dx.doi.org/10.2174/138945012802429750
DOI https://dx.doi.org/10.2174/138945012802429750 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MEET THE GUEST EDITOR [Hot Topic: Modern Omics-Based Platform for High Throughput Screening for Novel Drug Targets (Part 2) (Guest Editor: Canhua Huang)]
Combinatorial Chemistry & High Throughput Screening Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of a Novel Series of Indole-3- Carboxamide Derivatives for Cancer Treatment as EGFR Inhibitors
Letters in Drug Design & Discovery Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Nucleosome Positioning Based on the Sequence Word Composition
Protein & Peptide Letters Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents Nanotechnology: Nanomedicine, Nanotoxicity and Future Challenges
Nanoscience & Nanotechnology-Asia Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets Carcinogenesis and Diabetic Wound Healing: Evidences of Parallelism
Current Diabetes Reviews Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine
Current Cancer Drug Targets Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer
Current Drug Metabolism Histone Variant H2A.Z Can Serve as a New Target for Breast Cancer Therapy
Current Medicinal Chemistry Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Erythropoietin Enhances the Cytotoxic Effect of Hydrogen Peroxide on Colon Cancer Cells
Current Pharmaceutical Biotechnology Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials Pathogenic Genes Selection Model of Genetic Disease based on Network Motifs Slicing Feedback
Current Proteomics